Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

The Battle of the Biologics and Biosimilars Continues

XTALKS VITALS NEWS

A major patent on Humira® may expire December 2016 and there is much debate over its renewal by the patent trial and appeal board.

Tweetables from this article:

Tweet:  Humira® mimics endogenous cellular activity and reduces expression tumor necrosis factor (TNF)

Share this!

September 12, 2016 | by Kelly Daescu

The drug Humira®,produced by AbbVie Inc., specifically targets several autoimmune conditions including rheumatoid arthritis. Humira® mimics endogenous cellular activity and reduces expression tumor necrosis factor (TNF), an important regulator of inflammation. It is the top-selling drug in the world, but it comes with an expensive price tag, ranging from approximately, $20,000 to $50,000 a year.

A major patent on Humira® may expire December 2016 and there is much debate over its renewal by the patent trial and appeal board. The FDA is recommending green-lighting production of generic competitor biosimilars, and pharmaceutical giants like Amgen and Pfizer are crossing their fingers that the patent will expire since their generic versions are ready to market. Amgen, in fact, has already submitted a request to market a Humira® biosimilar to the FDA, and AbbVie responded with a lawsuit.



AbbVie says “not so fast” as they attempt to block the threat to their niche. They tout Amgen as a hypocrite, for Amgen staunchly defended its own biologic called Neupogen® and fought Novartis’ biosimilar Zarxio from being approved. Amgen defended its own biologic exclusivity by citing the difficulty involved with production, manufacturing, and distribution of such innovative and complex substances. The tables have turned as Humira® fights Amgen’s for similar reasons. Indeed, research and development for making such targeted, advanced treatment costs billions of dollars.

The competing drug companies producing the generic alternatives are resting on the Biologics Price Competition and Innovation Act (BPCIA) that was passed in 2010 to facilitate development of biosimilars. This year, there has been another proposal called the Price Relief, Innovation and Competition for Essential Drugs (PRICED) Act. It piggybacks on the BPCIA by proposing the previous 12-year biologic exclusivity previously granted be limited to only 7 years.

No matter how the battle between AbbVie and its competitors turn out, this kind of innovative technology will continue to improve. Europe has had biosimilars available for ten years, and no matter how much industry fights it, with the potential patent expiry of the world’s top-selling drug, it appears that more and more biosimilars may become available in the U.S in the near future.


Keywords: Humira, FDA, Biosimilars


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New Self-Injectable Form of Lupus Drug Approved by the FDA

July 25, 2017 - Patients with systemic lupus erythematosus (SLE) will now have the option to self-inject their medication thanks to the FDA approval of GSK’s reformulated lupus drug, Benlysta (belimumab).

Featured In: Biotech News


Canadian Chicken Farmers to Further Reduce Use of Antibiotics

July 24, 2017 - The Chicken Farmers of Canada, a national group dedicated to supporting poultry farmers and helping them meet consumer demand for chicken, has announced their strategy for eliminating the use of certain antimicrobials in meat production.

Featured In: Food News


Neonatal MRI Medical Device Approved by the FDA

July 24, 2017 - Medical device maker Aspect Imaging has received US Food and Drug Administration (FDA) approval for its Embrace Neonatal MRI System.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets from #AAIC17

REGISTER FOR THESE WEBINARS

Into the Great Wide Open: PTC’s Transformation & Global Journey to Bring Patients a First Ever Rare Disease Therapy


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.